中西医结合治疗慢乙肝及对T淋巴细胞亚群的影响

目的:观察疗肝3号联合拉米夫定治疗慢性乙型肝炎(CHB)的疗效及对T淋巴细胞亚群的影响。方法:80例CHB患者随机分为治疗组和对照组,治疗组40例为联合应用拉米夫定和疗肝3号治疗;对照组40例单用拉米夫定,疗程均为18个月,每3个月检测肝功能、乙型肝炎病毒血清学标志物、HBV DNA、T淋巴细胞亚群。结果:在治疗18个月时,治疗组和对照组的HBV DNA阴转率分别为77.5%和67.5%,差异无显著性意义(P>0.05),停药6个月后治疗组在HBV-DNA阴转HBeAg/抗-HBe血清转换、HBeAg阴转、及临床疗效上明显优于对照组,差异具有显著性(P<0.05)。治疗组外周血CD4亚群水平上调,CD4/CD8比值趋于正常,停药6个月后仍持续保持高水平,与对照组相比有显著性差异(P<0.05)。提示:拉米夫定联合疗肝3号有调节慢性乙型肝炎患者细胞免疫水平的作用,从而提高治疗CHB的疗效。

Effect of Liaogansanhao and Lamivudine Combination Therapy on Patients with Chronic Hepatitis B and Influence on T-cell Subset

Objective:To observe the effect of combined application of liaogansanhao and lamivudine in treating patients with chronic hepatitis B(CHB) and its infuence on T-cell subset.Methods:80 patients were enrolled and randomized into two groups:the treated group(40 cases) and the control group(40 cases).The treated group received liaogansanhao and lamivudine simultaneously for 18 months.The control group received lamivudine alone for 18 months.Liver function,virological parameters,serum HBV DNA and T-cell subset were evaluated.Results:After 18 months treatment,there was no difference in HBV DNA negative rate between treated and control groups(77.5%vs67.5%,P>0.05).But there was significant difference between treated and control groups such as HBV DNA negative rate,HBeAg/HBeAb blood lipid negative,HBeAg negative rate,clinical effect an so on after the treatment was over 6 months.CD4 T-cells levels increased and CD4/CD8 became normal,it could keep high level after the treatment was over 6 months.There was significant difference between treated and control groups(P<0.05) Conclusions:Combined application of liaogansanhao and lamivudine could adjust the T-cell subset level and enhance the therapeutic effect in treating CHB.